Skip to main content Accessibility help
×
×
Home

Rubinstein–Taybi syndrome: clinical and molecular overview

  • Jeroen H. Roelfsema (a1) and Dorien J.M. Peters (a1)
Abstract

Rubinstein–Taybi syndrome is characterised by mental retardation, growth retardation and a particular dysmorphology. The syndrome is rare, with a frequency of approximately one affected individual in 100 000 newborns. Mutations in two genes – CREBBP and EP300 – have been identified to cause the syndrome. These two genes show strong homology and encode histone acetyltransferases (HATs), which are transcriptional co-activators involved in many signalling pathways. Loss of HAT activity is sufficient to account for the phenomena seen in Rubinstein–Taybi patients. Although some mutations found in CREBBP are translocations, inversions and large deletions, most are point mutations or small deletions and insertions. Mutations in EP300 are comparatively rare. Extensive screening of patients has revealed mutations in CREBBP and EP300 in around 50% of cases. The cause of the syndrome in the remaining patients remains to be identified, but other genes could also be involved. Here, we describe the clinical presentation of Rubinstein–Taybi syndrome, review the mutation spectrum and discuss the current understanding of causative molecular mechanisms.

Copyright
Corresponding author
*Corresponding author: Dorien Peters, Dept of Human Genetics, Center for Human and Clinical Genetics, Leiden University Medical Center, Postzone S-04-P, PO Box 9600, 2300 RC Leiden, The Netherlands. Tel: 31 71 5269490; Fax: 31 71 5268285; E-mail: d.j.m.peters@lumc.nl
References
Hide All
1Hennekam, R.C.M. et al. (1989) Rubinstein–Taybi Syndrome in a mother and son. Eur J Pediatr 148, 439-441
2Marion, R.W., Garcia, D.M., Karasik, J.B. (1993) Apparent dominant transmission of the Rubinstein–Taybi syndrome. Am J Med Genet 46, 284-287
3Petrij, F. et al. (2000) Diagnostic analysis of the Rubinstein–Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations. J Med Genet 37, 168-76
4Petrij, F. et al. (1995) Rubinstein–Taybi syndrome is caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351
5Imaizumi, K. and Kuroki, Y. (1991) Rubinstein–Taybi syndrome with de novo reciprocal translocation t(2;16)(p13.3;p13.3). Am J Med Genet 38, 636-639
6Tommerup, N., van der Hagen, C.B. and Heiberg, A. (1991) Tentative assignment of a locus for Rubinstein–Taybi Syndrome to 16p13.3 by a de novo reciprocal translocation, t(7;16)(q34;p13.3). Cytogenet Cell Genet 58, 2002
7Lacombe, D. et al. (1992) Confirmation of assignment of a locus for Rubinstein–Taybi syndrome gene to 16p13.3. Am J Med Genet 44, 126-128
8Breuning, M.H. et al. (1993) Rubinstein–Taybi Syndrome caused by submicroscopic deletions of chromosome 16. Am J Hum Genet 52, 249-54
9Bartsch, O. et al. (2005) DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein–Taybi syndrome (RSTS) and in another patient with incomplete RSTS. Hum Genet 117, 485-493
10Roelfsema, J.H. et al. (2005) Genetic Heterogeneity in Rubinstein–Taybi Syndrome: Mutations in Both the CBP and EP300 Genes Cause Disease. Am J Hum Genet 76, 572-580
11Rubinstein, J.H. and Taybi, H. (1963) Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome. Am J Dis Child 105, 588-608
12Michail, J., Matsoukas, J. and Theodorou, S. (1957) Arched, clubbed thumb in strong abduction-extension & other concomitant symptoms. Rev Chir Orthop Reparatrice Appar Mot 43, 142-146
13Stevens, C.A. and Bhakta, M.G. (1995) Cardiac abnormalities in the Rubinstein-Taybi syndrome. Am J Med Genet 59, 346-348
14Hennekam, R.C.M. et al. (1990) Rubinstein–Taybi syndrome in the Netherlands. Am J Med Genet Suppl. 6, 17-29
15Wiley, S. (2003) Rubinstein-Taybi syndrome medical guidelines. Am J Med Genet 119, 101-110
16Rubinstein, J.H. (1990) Broad thumb-hallux (Rubinstein–Taybi) Syndrome 1957-1988. Am J Med Genet Suppl. 6, 3-16
17Hennekam, R.C.M., Boogaard, M.-J. and Doorne, J.M. (1991) A cephalometric study in Rubinstein–Taybi syndrome. J Craniofac Genet Dev Biol 11, 33-40
18Hennekam, R.C.M. et al. (1990) Metacarpophalangeal pattern profile analysis in Rubinstein–Taybi Syndrome. Am J Med Genet Suppl. 6, 48-50
19Hennekam, R.C. et al. (1993) Deletion at chromosome 16p13.3 as a cause of Rubinstein-Taybi syndrome: clinical aspects. Am J Hum Genet 52, 255-262
20Hennekam, R.C.M. et al. (1992) Psychological and speech studies in Rubinstein–Taybi syndrome. Am J Mental Retard 96, 645-660
21Miller, R.W. and Rubinstein, J.H. (1995) Tumors in Rubinstein–Taybi syndrome. Am J Med Genet 56, 112-115
22Hennekam, R.C.M., Stevens, C.A. and van de Kamp, J.J.P. (1990) Etiology and recurrence risk in Rubinstein–Taybi Syndrome. Am J Med Genet Suppl. 6, 56-64
23Sobel, R.A. and Woerner, S. (1981) Rubinstein–Taybi syndrome and nasopharyngeal rhabdomyosarcoma. J Pediatr 99, 1000-1001
24Bonioli, E. and Bellini, C. (1992) Rubinstein–Taybi Syndrome and pheochromocytoma. Am J Med Genet 44, 386
25Bilir, B.M., Bilir, N. and Wilson, G.N. (1990) Intracranial angioblastic meningioma and an aged appearance in a woman with Rubinstein–Taybi Syndrome. Am J Med Genet Suppl. 6, 69-72
26Cambiaghi, S. et al. (1994) Multiple pilomatricomas in Rubinstein–Taybi syndrome: a case report. Pediatr Dermatol 11, 21-25
27Urlinger, S. et al. (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 97, 7963-7968
28Russell, N.A., Hoffman, H.J. and Bain, H.W. (1971) Intraspinal neurilemoma in association with the Rubinstein–Taybi syndrome. Pediatrics 47, 444-447
29Jonas, D.M., Heilbron, D.C. and Ablin, A.R. (1978) Rubinstein–Taybi syndrome and acute leukemia. J Pediatr. 92, 851-852
30Goodfellow, A., Emmerson, R.W. and Calvert, H.T. (1980) Rubinstein–Taybi Syndrome and spontaneous keloids. Clin Exp Dermatol 5, 369-371
31Rohlfing, B., Lewis, K. and Singleton, E.B. (1971) Rubinstein–Taybi syndrome. Report of an unusual case. Am J Dis Child 121, 71-74
32Kwok, R.P. et al. (1994) Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370, 223-226
33Lundblad, J.R. et al. (1995) Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 374, 85-88
34Chrivia, J.C. et al. (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365, 855-859
35Shi, Y. and Mello, C. (1998) A CBP/p300 homolog specifies multiple differentiation pathways in Caenorhabditis elegans. Genes Dev 12, 943-955
36Bordoli, L. et al. (2001) Plant orthologs of p300/CBP: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins. Nucleic Acids Res. 29, 589-597
37Giles, R.H., Peters, D.J.M. and Breuning, M.H. (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14, 178-183
38Goodman, R.H. and Smolik, S. (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14, 1553-1577
39Bannister, A.J. and Kouzarides, T. (1996) The CBP co-activator is a histone acetyltransferase. Nature 384, 641-643
40Ogryzko, V.V. et al. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959
41Gu, W. and Roeder, R.G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606
42Roth, S.Y., Denu, J.M. and Allis, C.D. (2001) Histone acetyltransferases. Annu Rev Biochem 70, 81-120
43Kung, A.L. et al. (2000) Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14, 272-277
44Oike, Y. et al. (1999) Truncated CBP protein leads to classical Rubinstein–Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet 8, 387-396
45Tanaka, Y. et al. (2000) Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mech Dev 95, 133-145
46Yao, T.P. et al. (1998) Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93, 361-372
47Kalkhoven, E. (2004) CBP and p300: HATs for different occasions. Biochem Pharmacol 68, 1145-1155
48Kasper, L.H. et al. (2006) Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol 26, 789-809
49Kwok, R.P., Liu, X.T. and Smith, G.D. (2006) Distribution of co-activators CBP and p300 during mouse oocyte and embryo development. Mol Reprod Dev 73, 885-894
50Partanen, A., Motoyama, J. and Hui, C.C. (1999) Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis. Int J Dev Biol 43, 487-494
51Kawasaki, H. et al. (1998) Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 393, 284-289
52Ugai, H., Uchida, K., Kawasaki, H. and Yokoyama, K.K. (1999) The coactivators p300 and CBP have different functions during the differentiation of F9 cells. J Mol Med 77, 481-494
53Roth, J.F. et al. (2003) Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J 22, 5186-5196
54Tanaka, Y. et al. (1997) Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein–Taybi syndrome. Proc Natl Acad Sci U S A 94, 10215-10220
55Bartholdi, D. et al. (2007) Genetic heterogeneity in Rubinstein–Taybi Syndrome: delineation of the phenotype of the first patients carrying mutations in EP300. J Med Genet 44, 327-333
56Petrij, F. et al. (2000) Rubinstein–Taybi syndrome caused by a De Novo reciprocal translocation t(2;16)(q36.3;p13.3). Am J Med Genet 92, 47-52
57Giles, R.H. et al. (1997) Construction of a 1.2-Mb contig surrounding and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3. Genomics 42, 96-114
58Troke, P.J., Kindle, K.B., Collins, H.M. and Heery, D.M. (2006) MOZ fusion proteins in acute myeloid leukaemia. Biochem Soc Symp 73, 23-39
59Bartsch, O. et al. (2006) Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein–Taybi syndrome. Hum Genet 120, 179-186
60Schouten, J.P. et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30, e57
61Bentivegna, A. et al. (2006) Rubinstein–Taybi Syndrome: spectrum of CREBBP mutations in Italian patients. BMC Med Genet 7, 77
62Bartsch, O. et al. (1999) FISH studies in 45 patients with Rubinstein–Taybi syndrome: deletions associated with polysplenia, hypoplastic left heart and death in infancy. Eur J Human Genet 7, 748-756
63Coupry, I. et al. (2004) Analysis of CBP (CREBBP) gene deletions in Rubinstein–Taybi syndrome patients using real-time quantitative PCR. Hum Mutat 23, 278-284
64Udaka, T. et al. (2006) Screening for Partial Deletions in the CREBBP Gene in Rubinstein–Taybi Syndrome Patients Using Multiplex PCR/Liquid Chromatography. Genet Test 10, 265-271
65Kalkhoven, E. et al. (2003) Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein–Taybi syndrome. Hum Mol Genet 12, 441-450
66Udaka, T. et al. (2005) Comprehensive screening of CREB-binding protein gene mutations among patients with Rubinstein–Taybi syndrome using denaturing high-performance liquid chromatography. Congenit Anom 45, 125-131
67Bartsch, O. et al. (2002) Molecular studies in 10 cases of Rubinstein–Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP. J Med Genet 39, 496-501
68Coupry, I. et al. (2002) Molecular analysis of the CBP gene in 60 patients with Rubinstein–Taybi syndrome. J Med Genet 39, 415-421
69Murata, T. et al. (2001) Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein–Taybi syndrome. Hum Mol Genet 10, 1071-1076
70Zimmermann, N. et al. (2007) Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome. Eur J Hum Genet advance online publication 14 February 2007; doi: 10.1038/sj.ejhg.5201791
71Bito, H., Deisseroth, K. and Tsien, R.W. (1996) CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell 87, 1203-1214
72Abel, T. et al. (1997) Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell 88, 615-626
73Atkins, C.M. et al. (1998) The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1, 602-609
74Bourtchouladze, R. et al. (2003) A mouse model of Rubinstein–Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci U S A 100, 10518-10522
75Wood, M.A. et al. (2006) A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn Mem 13, 609-617
76Oike, Y. et al. (1999) Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood 93, 2771-2779
77Alarcon, J.M. et al. (1999) Chromatin acetylation, memory, and LTP are impaired in CBP +/− mice: a model for the cognitive deficit in Rubinstein–Taybi syndrome and its amelioration. Neuron 42, 947-959
78Korzus, E., Rosenfeld, M.G. and Mayford, M. (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961-972
79Wood, M.A. et al. (2005) Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem 12, 111-119
80Josselyn, S.A. (2005) What's right with my mouse model? New insights into the molecular and cellular basis of cognition from mouse models of Rubinstein–Taybi Syndrome. Learn Mem 12, 80-83
81Gayther, S.A. et al. (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24, 300-303
82Ozdag, H. et al. (2002) Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br J Cancer 87, 1162-1165
83Kishimoto, M. et al. (2005) Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 11, 512-519
84Hennekam, R.C. (2006) Rubinstein–Taybi syndrome. Eur J Human Genet 14, 981-985
85Wallerstein, R. et al. (1997) Submicroscopic deletions at 16p13.3 in Rubinstein–Taybi syndrome: frequency and clinical manifestations in a North American population. J Med Genet 34, 203-206
Gorlin, R.J., Cohen, M.M. and Hennekam, R.C.M. (2001). Syndromes of the Head and Neck. [Oxford Monographs on Medical Genetics (No. 42)], Oxford University Press, New York
Petrij, F. et al. (2004) CBP and the Rubinstein–Taybi syndrome. In Inborn Errors of Development, 1st Edn (Epstein, CJ et al. , Eds), pp 728746, Oxford University Press, New York
Hallam, T.M. and Bourtchouladze, R. (2006) Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. Cell Mol Life Sci 63, 17251735.

The Online Mendelian Inheritance in Man (OMIM) website provides a description of Rubinstein–Taybi syndrome (Rubinstein–Taybi syndrome, OMIM 180849; CREBBP or CBP, OMIM 600140; EP300 or p300, OMIM 602700):

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed